*Some Market data delayed by 15 mins.

Trevi Therapeutics, Inc. Common Stock

Symbol: TRVI (NASDAQ)
2.64 ▼ (-4.66%) -0.129

Company Description:
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Key Stats
  • Today's Open: $2.73
  • Today's High: $2.95
  • Today's Low: $2.499
  • Today's Volume: 286.11K
  • Yesterday Close: $2.77
  • Yesterday High: $2.96
  • Yesterday Low: $2.72
  • Yesterday Volume: 237.53K
  • Last Min Volume: 0
  • Last Min High: $2.641
  • Last Min Low: $2.641
  • Last Min VWAP: $0
Company Profile
  • Name: Trevi Therapeutics, Inc. Common Stock
  • Website: https://www.trevitherapeutics.com
  • Listed Date: 2019-05-03
  • Location: NEW HAVEN, CT
  • Market Status: Active
  • CIK Number: 0001563880
  • SIC Code: 2834
  • SIC description: PHARMACEUTICAL PREPARATIONS
  • Market Cap: $186.65M
  • Round Lot: 100
  • Outstanding Shares: 70.44M
  • Asset Type: CS
RECENT FILINGS FOR TRVI
Filing DateFiling TypeFormat
2024-06-144View
2024-06-144View
2024-06-144View
2024-06-144View
2024-06-144View
2024-06-144View
2024-06-138-KView
2024-05-314View
2024-05-29144View
2024-05-244View
2024-05-224View
2024-05-21SC 13D/AView
2024-05-144View
2024-05-0710-QView
2024-05-078-KView
2024-04-29ARSView
2024-04-26DEFA14AView
2024-04-26DEF 14AView
2024-04-25SC 13G/AView
2024-03-20S-8View
Latest News

 

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money. Copyright© 2024, 247MarketNews inc.